产品
编 号：F259529
分子式：C26H28O11
分子量：516.49
分子式：C26H28O11
分子量：516.49
产品类型
规格
价格
是否有货
结构图
CAS No: 209746-59-8
产品详情
生物活性：
T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 μM and 2.3 μM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.
体内研究：
T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney. Orally administered T-1095 (3-30 mg/kg) increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels.With long-term T-1095 (0.01% or 0.1% T-1095 mixed diet; for 28 days) treatment, both blood glucose and HbA1c levels were reduced in streptozotocin (STZ)-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice.
T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 μM and 2.3 μM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.
体内研究：
T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney. Orally administered T-1095 (3-30 mg/kg) increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels.With long-term T-1095 (0.01% or 0.1% T-1095 mixed diet; for 28 days) treatment, both blood glucose and HbA1c levels were reduced in streptozotocin (STZ)-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备